Third line H. pylori eradication therapy with sitafloxacin, amoxicillin and vonapraza
Phase 3
- Conditions
- H. pylori-positve patients after the 2nd line eradication failure
- Registration Number
- JPRN-UMIN000022235
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Even for gyrA mutation positive H.pylori, eradication rate of 7-day VAS regimen achieved 89.7% of successful eradication, which is obviously higher than 10-day EAS regimen. D91 gyrA mutation-positive H. pylori strains were completely eradicated by 7-day VAS regimen. This finding is important in terms of sufficiently reducing the risk of acquiring double mutations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with allergy for quinolones 2. Patients with allergy for PPIs 3. Patients with severe liver injury and/or severe renal damage 4. Pregnancy or possible pregnancy 5. Patients who were recognized as inappropriate for entry
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method